Teva Pharmaceutical Industries has issued US$4bn of dual-currency sustainability-linked senior notes. The generic drug maker will use the proceeds, along with cash in hand, to fund a debt tender offer to purchase, for cash, its 1.25% Notes due 2023, its 2.8% Notes due 2023, its 3.25% Notes due 2022, its 2.95% Notes due 2022, its…
Home Healthcare Markets International Business Israel: Teva Pharma plans US$4bn sustainability-linked notes to buy back notes due...